Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Emerson Resources Inc. , a premier ... the Company’s Chief Executive Officer and Chairman of the ... of service. As part of Emerson Resources’ planned leadership ... named as Dr. Signorino’s successor. , Dr. Signorino ... made a significant contribution to the field during his ...
(Date:5/21/2013)... Revolutionary Science, the manufacturer of the ... today that they have expanded their colony counter product ... IntelliCount, InCount and ImpressCount. These affordable colony counters ... in food microbiology and pharmaceutical manufacturing. , The previously ... A bright white enclosure with jet black accents represent ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 SoundConnect ... communications platform, Microsoft Lync, for customers in Canada. ... software and will allow businesses and organizations to ... Last month, SoundConnect released Lync in the United States. ... paired with the product release in Canada, SoundConnect now ...
(Date:5/20/2013)... May 21, 2013 Grace Century ... in “game-changing” life science and health related private equity ... to its International Project Team. Dergham's expertise in finance ... multi-cultural depth to Grace Century as it continues to ... , Ms. Dergham holds both an under graduate degree ...
Breaking Biology Technology:Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
... CRY ),a biomaterials, medical device and tissue ... been named vice president, general,counsel, effective September 4, ... Anderson, chairman, president and chief executive officer of ... be responsible for all corporate,legal and governance activities, ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer is scheduled to present at the 20th,Annual ... 2007,at 8:30 a.m. Eastern Daylight Time. The conference ...
... III Clinical Development and ... in Developing Countries, LEUVEN, Belgium, September 4 ... focused on vascular disease, today,announced the successful completion ... (Hyderabad, India) for the manufacture of,THR-100, a novel ...
Cached Biology Technology:CryoLife Names Philip Theodore as Vice President, General Counsel 2ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4
(Date:5/20/2013)... A novel vaccine study from South Dakota State ... be unveiled at the American Association of Pharmaceutical Scientists, ... Monday, May 20 - Wednesday, May 22 at the ... main goal of a vaccine is to stimulate the ... the disease", explained Dr. Hemachand Tummala, assistant professor of ...
(Date:5/19/2013)... electricity-producing bacteria that can grow using hydrogen gas as ... sole source of carbon. Researchers at the University ... General Meeting of the American Society for Microbiology. , ... on hydrogen," says Amit Kumar, a researcher on the ... the Lovley Lab Group at the university. , Under ...
(Date:5/18/2013)... 18, 2013) Research presented at Digestive Disease ... health through diet and lifestyle. , Individuals ... reduced muscle strength, fatigue and poor quality of ... are in remission. A randomized, double blind, placebo-controlled ... D supplementation corresponded to significant relief of these ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3
... samples influence prescribing, finds a small but representative US ... But they also think that other doctors are more ... the data show. , In March 2003, the research ... Obstetricians and Gynecologists about their relationships with the pharmaceutical ...
... as many infant deaths than previously estimated, according to a ... Control and Prevention. , The analysis, published today in Pediatrics, ... 37 completed weeks gestation, contributed to more than one-third of ... "We have long known that babies born too soon face ...
... people with backache caused by nerve root pain ?commonly ... discover if therapeutic ultrasound can help their condition. , ... Centre for Rehabilitation Science need 30 volunteers aged 22-55 ... are not pregnant and have not had previous spinal ...
Cached Biology News:Free drug samples influence prescribing, say one in three doctors 2New study: Preterm birth causes one-third of all infant deaths 2
... Polystyrene covers can be ... Ridged covers for stacking ... Non-ridged covers for use with ... covers, ridged and non-ridged, are ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
... Chromatography requirements, IonQuest will provide ... The newly developed conductivity detector has ... ultra-low drift . The use ... creates even higher sensitivities for anions, ...
... chromatography system . The sensitive conductivity detector ... 5000S, houses the measuring cell in a thermostatted ... available. Data processing is provided by the ... by the high pressure CE 4100 dual piston ...
Biology Products: